Abstract | PURPOSE: SUBJECTS AND METHODS: RESULTS: The mean polymorphic nuclear cell count on admission was 231 cells/mm(3). Ceftazidime therapy was well tolerated. Twenty-five (66%) patients responded with clinical improvement and complete resolution of fever within 48 h after initiation of ceftazidime therapy. Thirty-two (84%) patients were afebrile after 72 h of therapy. Thirty-three patients (87%) remained on unmodified ceftazidime therapy throughout their hospitalization. Five patients (13%) subsequently required modification of the treatment regimen for various reasons. Mean duration of fever and neutropenia were 2 (1-10) days and 4 (1-11) days, respectively. None of the patients discontinued therapy because of adverse effects. No positive blood cultures were obtained. No events of septic shock were observed. Mean duration of hospitalization was 6 days (range 3-12). CONCLUSION:
|
Authors | Pnina Chernobelski, Konstantin Lavrenkov, Doron Rimar, Klaris Riesenberg, Francisc Schlaeffer, Samuel Ariad, Wilmosh Mermershtain |
Journal | Chemotherapy
(Chemotherapy)
Vol. 52
Issue 4
Pg. 185-9
( 2006)
ISSN: 0009-3157 [Print] Switzerland |
PMID | 16675902
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Ceftazidime
|
Topics |
- Adult
- Aged
- Anti-Bacterial Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Ceftazidime
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Neutropenia
(chemically induced, drug therapy)
- Prospective Studies
- Survival Rate
- Time Factors
- Treatment Outcome
|